266 related articles for article (PubMed ID: 15026023)
1. Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan.
Kuno-Sakai H; Kimura M; Watanabe H
Biologicals; 2004 Mar; 32(1):29-35. PubMed ID: 15026023
[TBL] [Abstract][Full Text] [Related]
2. Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan.
Pichichero ME; Decker MD
Biologicals; 2005 Mar; 33(1):59. PubMed ID: 15713557
[No Abstract] [Full Text] [Related]
3. Overview of currently available Japanese acellular pertussis vaccines and future problems.
Kamiya H; Nii R
Tokai J Exp Clin Med; 1988; 13 Suppl():45-9. PubMed ID: 3273618
[TBL] [Abstract][Full Text] [Related]
4. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
[TBL] [Abstract][Full Text] [Related]
5. Composition of acellular pertussis and combination vaccines: a general review.
Jadhav SS; Gairola S
Biologicals; 1999 Jun; 27(2):105-10. PubMed ID: 10600195
[TBL] [Abstract][Full Text] [Related]
6. Restricted antibody response to Bordetella pertussis filamentous hemagglutinin induced by whole-cell and acellular pertussis vaccines.
Asgarian-Omran H; Golara M; Abdolmaleki S; Navabi SS; Alipour H; Khoshnoodi J; Hemmati A; Zarei S; Jeddi-Tehrani M; Shokri F
Infect Dis (Lond); 2016 Feb; 48(2):127-32. PubMed ID: 26439274
[TBL] [Abstract][Full Text] [Related]
7. Pertussis vaccines: present status.
Christodoulides M
Adv Biotechnol Processes; 1990; 13():169-99. PubMed ID: 2185783
[TBL] [Abstract][Full Text] [Related]
8. Overview of recent clinical trials of acellular pertussis vaccines.
Miller E
Biologicals; 1999 Jun; 27(2):79-86. PubMed ID: 10600188
[TBL] [Abstract][Full Text] [Related]
9. Modified intra-cerebral challenge assay for acellular pertussis vaccines: comparisons among whole cell and acellular vaccines.
Gaines-Das R; Horiuchi Y; Zhang SM; Newland P; Kim Y; Corbel M; Xing D
Vaccine; 2009 Nov; 27(49):6824-32. PubMed ID: 19765397
[TBL] [Abstract][Full Text] [Related]
10. Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children.
Vickers D; Ross AG; Mainar-Jaime RC; Neudorf C; Shah S
CMAJ; 2006 Nov; 175(10):1213-7. PubMed ID: 17098950
[TBL] [Abstract][Full Text] [Related]
11. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
[TBL] [Abstract][Full Text] [Related]
12. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin.
Ginnaga A; Morokuma K; Aihara K; Sakou M; Imaizumi A; Suzuki Y; Sato H; Sato Y; Ueda K; Kuno-Sakai H
Tokai J Exp Clin Med; 1988; 13 Suppl():59-69. PubMed ID: 2908528
[TBL] [Abstract][Full Text] [Related]
13. Protection against pertussis by Takeda's acellular pertussis vaccine: household contact studies in Kawasaki City, Japan.
Kato T; Kaku H; Arimoto Y
Tokai J Exp Clin Med; 1988; 13 Suppl():35-8. PubMed ID: 3078808
[TBL] [Abstract][Full Text] [Related]
14. Development of acellular pertussis vaccines.
Sato Y; Sato H
Biologicals; 1999 Jun; 27(2):61-9. PubMed ID: 10600185
[TBL] [Abstract][Full Text] [Related]
15. Aerosol infection test for evaluation of pertussis vaccine.
Syukuda Y; Watanabe H; Suehara A; Fujii S; Kuno-Sakai H; Kimura M
Tokai J Exp Clin Med; 1988; 13 Suppl():71-7. PubMed ID: 2908529
[TBL] [Abstract][Full Text] [Related]
16. Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model.
Marr N; Oliver DC; Laurent V; Poolman J; Denoël P; Fernandez RC
Vaccine; 2008 Aug; 26(34):4306-11. PubMed ID: 18582518
[TBL] [Abstract][Full Text] [Related]
17. Engineering bacterial toxin for the development of new vaccine against pertussis.
Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R
Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870
[TBL] [Abstract][Full Text] [Related]
18. WHO working group on standardisation and control of acellular pertussis vaccines--report of a meeting held on 16-17 March 2006, St. Albans, United Kingdom.
Xing DK; Corbel MJ; Dobbelaer R; Knezevic I
Vaccine; 2007 Apr; 25(15):2749-57. PubMed ID: 17368348
[TBL] [Abstract][Full Text] [Related]
19. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of an acellular pertussis vaccine in Japanese children during a non-epidemic period: a matched case-control study.
Okada K; Ohashi Y; Matsuo F; Uno S; Soh M; Nishima S
Epidemiol Infect; 2009 Jan; 137(1):124-30. PubMed ID: 18474125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
